CO2021014008A2 - Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento - Google Patents
Compuestos farmacéuticos para el tratamiento de trastornos mediados por complementoInfo
- Publication number
- CO2021014008A2 CO2021014008A2 CONC2021/0014008A CO2021014008A CO2021014008A2 CO 2021014008 A2 CO2021014008 A2 CO 2021014008A2 CO 2021014008 A CO2021014008 A CO 2021014008A CO 2021014008 A2 CO2021014008 A2 CO 2021014008A2
- Authority
- CO
- Colombia
- Prior art keywords
- complement
- mediated disorders
- pharmaceutical compounds
- treatment
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
Abstract
RESUMEN La presente descripción proporciona compuestos farmacéuticos para tratar trastornos médicos, tales como trastornos mediados por complemento, incluidos los trastornos mediados por el complemento C1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962822553P | 2019-03-22 | 2019-03-22 | |
US201962951669P | 2019-12-20 | 2019-12-20 | |
PCT/US2020/024017 WO2020198062A1 (en) | 2019-03-22 | 2020-03-20 | Pharmaceutical compounds for the treatment of complement mediated disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021014008A2 true CO2021014008A2 (es) | 2021-10-29 |
Family
ID=72610019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0014008A CO2021014008A2 (es) | 2019-03-22 | 2021-10-20 | Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230085372A1 (es) |
EP (1) | EP3941462A4 (es) |
JP (1) | JP2022519924A (es) |
KR (1) | KR20220004024A (es) |
CN (1) | CN113795249A (es) |
AU (1) | AU2020245434A1 (es) |
CA (1) | CA3134608A1 (es) |
CO (1) | CO2021014008A2 (es) |
MX (1) | MX2021011507A (es) |
WO (1) | WO2020198062A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022066774A1 (en) * | 2020-09-23 | 2022-03-31 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
CN116472065A (zh) * | 2020-10-05 | 2023-07-21 | 阿雷克森制药公司 | 治疗皮肌炎的方法 |
WO2022225960A1 (en) * | 2021-04-19 | 2022-10-27 | Rhode Island Hospital | Androgen receptor inhibition to treat sepsis and shock |
CN117209555A (zh) * | 2021-09-30 | 2023-12-12 | 中国科学院上海药物研究所 | 一类氰基化合物、其制备方法及用途 |
WO2023183405A2 (en) * | 2022-03-22 | 2023-09-28 | Alexion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
CN116440117A (zh) * | 2023-06-14 | 2023-07-18 | 四川省医学科学院·四川省人民医院 | 甲磺酸萘莫司他在制备治疗肾损伤或肾功能不全药物中的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000047461A (ko) * | 1998-12-29 | 2000-07-25 | 성재갑 | 트롬빈 억제제 |
BR0009678A (pt) * | 1999-04-09 | 2002-01-22 | Basf Ag | Compostos, composição farmacêutica, e, uso de compostos |
US7482376B2 (en) * | 2003-07-03 | 2009-01-27 | 3-Dimensional Pharmaceuticals, Inc. | Conjugated complement cascade inhibitors |
JP2010515729A (ja) * | 2007-01-10 | 2010-05-13 | アイアールエム・リミテッド・ライアビリティ・カンパニー | チャネル活性化プロテアーゼ阻害剤としての化合物および組成物 |
ES2647124T3 (es) * | 2012-06-28 | 2017-12-19 | Novartis Ag | Derivados de pirrolidina y su uso como moduladores de la ruta del complemento |
EA032690B1 (ru) * | 2014-02-25 | 2019-07-31 | Ачиллион Фармасьютикалс, Инк. | Арильные, гетероарильные и гетероциклические соединения для лечения опосредованных комплементом расстройств |
AR105808A1 (es) * | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos de amida para el tratamiento de trastornos médicos |
-
2020
- 2020-03-20 JP JP2021556758A patent/JP2022519924A/ja active Pending
- 2020-03-20 US US17/440,665 patent/US20230085372A1/en active Pending
- 2020-03-20 KR KR1020217033266A patent/KR20220004024A/ko unknown
- 2020-03-20 EP EP20777094.2A patent/EP3941462A4/en active Pending
- 2020-03-20 CA CA3134608A patent/CA3134608A1/en active Pending
- 2020-03-20 MX MX2021011507A patent/MX2021011507A/es unknown
- 2020-03-20 CN CN202080032493.0A patent/CN113795249A/zh active Pending
- 2020-03-20 WO PCT/US2020/024017 patent/WO2020198062A1/en active Application Filing
- 2020-03-20 AU AU2020245434A patent/AU2020245434A1/en not_active Abandoned
-
2021
- 2021-10-20 CO CONC2021/0014008A patent/CO2021014008A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN113795249A (zh) | 2021-12-14 |
JP2022519924A (ja) | 2022-03-25 |
KR20220004024A (ko) | 2022-01-11 |
EP3941462A4 (en) | 2023-04-05 |
CA3134608A1 (en) | 2020-10-01 |
AU2020245434A1 (en) | 2021-09-30 |
MX2021011507A (es) | 2021-12-15 |
WO2020198062A1 (en) | 2020-10-01 |
EP3941462A1 (en) | 2022-01-26 |
US20230085372A1 (en) | 2023-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021014008A2 (es) | Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
NI201900070A (es) | Compuestos heterocíclicos como inmunomoduladores | |
CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
CL2018003265A1 (es) | Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos. | |
DOP2016000295A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
CO2020013155A2 (es) | Moduladores de nlrp3 | |
CU20190073A7 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas | |
CL2020001138A1 (es) | Compuestos bicíclicos en puente como moduladores del receptor farnesoide x. | |
GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
BR112018001292A2 (pt) | métodos para melhor liberação de agentes ativos a tumores | |
CL2018003698A1 (es) | Oligonucleótidos antisentido para modular la expresión de htra1. | |
CO2019013016A2 (es) | Inhibidores pirazólicos de magl | |
CO2020000227A2 (es) | Moduladores de nlrp3 | |
BR112018073849A2 (pt) | compostos benzenossulfonamida e seu uso como agentes terapêuticos | |
CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
NI201801172A (es) | Nuevos compuestos para el tratamiento de enfermedades parasitarias | |
CO2017007076A2 (es) | Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo | |
CO2020005485A2 (es) | Administración oral de análogos del péptido glp-1 | |
EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
UY36081A (es) | Compuestos inhibidores de metaloenzima como fungicidas. | |
CL2018003109A1 (es) | Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos. | |
ECSP16074207A (es) | Pirazinas moduladoras de gpr6 | |
BR112017014189A2 (pt) | terapia de câncer com um parvovirus combinado com bevacizumabe |